Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 6:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Conditions
Alzheimer Disease
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects

NCT01992380
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Newport Beach, California • New Haven, Connecticut
Conditions
Alzheimer Disease
Interventions
flortaucipir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Not listed
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of Flortaucipir F 18

NCT02278367
Conditions
Alzheimer's Disease, Traumatic Brain Injury, Depression
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
5
States / cities
Phoenix, Arizona • New Haven, Connecticut • Las Vegas, Nevada + 2 more
Conditions
Alzheimer Disease
Interventions
Flortaucipir F18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years to 85 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
San Diego, California • Santa Ana, California • Delray Beach, Florida + 6 more
Completed Phase 1 Interventional Results available

18F-AV-1451 High Resolution Autopsy Study

NCT02350634
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years to 89 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Phoenix, Arizona • San Francisco, California
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 2

NCT01231971
Conditions
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), Significant Memory Concern (SMC), Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI)
Interventions
Florbetapir, Flortaucipir
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 43 more
Conditions
Alzheimer Disease
Interventions
Flortaucipir F18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years to 85 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
9
States / cities
Irvine, California • Delray Beach, Florida • Fort Myers, Florida + 6 more
Completed Phase 1 Interventional Results available

Tau Imaging in Professional Fighters

NCT02278354
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Augmenting Flortaucipir Dosimetry Estimates

NCT02336360
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 1 Interventional Results available

Flortaucipir PET Imaging in Subjects With FTD

NCT03040713
Conditions
Frontotemporal Dementia
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
La Jolla, California • San Francisco, California • Dallas, Texas
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

NFL LONG Prospective Study

NCT04263337
Conditions
Concussion, Brain
Interventions
[11C] PiB, [18F] PBR111, [18F] Flortaucipir
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years to 70 Years · Male only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
3
States / cities
Waltham, Massachusetts • Chapel Hill, North Carolina • Milwaukee, Wisconsin
Conditions
Alzheimer Disease
Interventions
[11C]-Pittsburgh Compound B ([11C]PiB), F 18 AV-1451 (Flortaucipir)
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Progressive Supranuclear Palsy, Corticobasal Degeneration
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
5
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 2 more
Recruiting No phase listed Observational

Depression and Driving

NCT05446805
Conditions
Depression, Drive
Interventions
F 18 AV-1451 (Flortaucipir), [11C]-Pittsburgh Compound B ([11C]PiB)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
150 participants
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Chronic Traumatic Encephalopathy
Interventions
florbetapir F 18, Flortaucipir F18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Male only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Phoenix, Arizona • Boston, Massachusetts
Completed Phase 3 Interventional Results available

18F-AV-1451 Autopsy Study

NCT02516046
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
30
States / cities
Phoenix, Arizona • Los Gatos, California • Newport Beach, California + 23 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Early-onset Alzheimer's Disease Study Protocol

NCT03507257
Conditions
Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Flortaucipir, Florbetaben, Fluorodeoxyglucose
Drug
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 64 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
18
States / cities
Sun City, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects

NCT02016560
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18, Flortaucipir F18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
20 Years and older
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
27
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 20 more
Conditions
Alzheimer Disease
Interventions
flortaucipir F18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
55 Years to 85 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Flortaucipir 18F PET Imaging in BIOCARD Study

NCT03052972
Conditions
Cognitive Decline
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

NCT04474405
Conditions
Alzheimer Disease
Interventions
Flortaucipir F18, Brain PET Scan, Whole body PET scan, Florbetapir F 18, Brain MRI
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
20 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Cypress, California • Newport Beach, California
Conditions
Alzheimer Disease, Cognitive Decline
Interventions
[18F]AV-1451, Positron Emission Tomography
Drug · Procedure
Lead sponsor
Neil M Rofsky, MD, MHA
Other
Eligibility
38 Years to 96 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Alzheimer Disease
Interventions
F 18 T807 Flortaucipir
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
St Louis, Missouri